Skip Navigation


Annals of Oncology Advance Access originally published online on November 7, 2005
Annals of Oncology 2006 17(2):330-333; doi:10.1093/annonc/mdj069
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/2/330    most recent
mdj069v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ogawa, Y.
Right arrow Articles by Seriu, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ogawa, Y.
Right arrow Articles by Seriu, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma

Y. Ogawa1,*, T. Hotta1, K. Tobinai2, T. Watanabe2, Y. Sasaki3, H. Minami3, Y. Morishima4, M. Ogura4 and T. Seriu5

1 Department of Hematology and Oncology, Tokai University School of Medicine, Isehara; 2 Hematology Division, National Cancer Center Hospital, Tokyo; 3 Division of Oncology and Hematology, National Cancer Center Hospital East, Kashiwa; 4 Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya; 5 Nihon Schering K.K., Osaka, Japan

* Correspondence to: Dr Y. Ogawa, Department of Hematology and Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, Kanagawa, Japan. Tel: +81-463-93-1121; Fax: +81-463-92-4511; E-mail: yoshioga{at}is.icc.u-tokai.ac.jp

Background: The primary objective of this study was to investigate the tolerability, efficacy and pharmacokinetic profile of oral fludarabine phosphate in relapsed patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL).

Patients and methods: Patients received fludarabine phosphate orally for 5 days, for a total of one to three cycles. Tolerability was assessed using the National Cancer Institute Common Toxicity Criteria. Efficacy was assessed using the International Workshop Criteria for NHL. Pharmacokinetic samples were taken on day 1 and day 5 of the first treatment cycle.

Results: Twelve patients were enrolled. One patient at 40 mg/m2/day developed grade 4 hyperuricemia. At 50 mg/m2/day, one patient developed grade 3 febrile neutropenia and grade 4 leukopenia, and another patient showed lasting grade 4 neutropenia. Most common toxicities included grade 3 or 4 lymphopenia (83%), leukopenia (50%) and neutropenia (50%). All the toxicities were reversible. The overall response rate was 67%. The AUC0–24h values on day 5 indicated a dose-dependent increase in systemically available 2-fluoro-arabinofuranosyl-adenine (2F-ara-A).

Conclusions: Oral fludarabine phosphate is safe and effective for relapsed patients with indolent B-NHL. The dose of 40 mg/m2/day is recommended for a following pivotal phase II study.

Key words: fludarabine phosphate, indolent B-cell non-Hodgkin's lymphoma, oral, pharmacokinetic


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.